
Opinion|Videos|December 16, 2024
Lung LCNEC Disease Histology and Prognosis
Author(s)Martin Dietrich, MD, PhD, Soo-Ryum Yang, MD
Panelists discuss the typical treatment approach for patients with lung large cell neuroendocrine carcinoma (LCNEC), the patient-specific factors considered in first-line treatment selection, insights from the ASCO 2024 retrospective studies on first-line systemic treatment outcomes, and key considerations for choosing a second-line treatment strategy.
Advertisement
Episodes in this series

- Given the limited therapeutic options for patients with lung LCNEC, what is your typical treatment approach?
- What patient-specific factors do you consider to guide your first-line treatment selection?
- Please share your thoughts on the ASCO 2024 retrospective studies examining first-line systemic treatment outcomes: 1. (
Nassar et al, ASCO 2024 ); 2. (Matteson et al., ASCO 2024 )- What are your key considerations for choosing a second-line treatment strategy?
- How has the tarlatamab approval in SCLC(
Ahn et al., NEJM 2023 ) impacted your treatment approach for patients with LCNEC?
Advertisement
Related to this article

The FDA approved giredestrant plus everolimus in ESR1-mutated breast cancer and neladalkib in ALK+ NSCLC, issued a CRL to ivonescimab, and more.

Daraxonrasib plus gemcitabine/nab-paclitaxel yielded a 60.7% ORR and 12.8-month median PFS in first-line metastatic pancreatic adenocarcinoma.

Sac-TMT improved OS vs treatment of physician’s choice in pretreated gastroesophageal adenocarcinoma, but TroFuse-015 missed its PFS secondary end point.

Gynecologic oncologists answer FAQs on LGSOC targeted therapy, PARP inhibitor maintenance, and emerging ADCs in ovarian cancer.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Jorge Cortes, MD, discusses response-based ponatinib dosing, mutation testing, and managing cardiovascular risk in resistant CML.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Plus Gemcitabine/Nab-Paclitaxel Generates Durable Responses in First-Line Metastatic PDAC
2
TroFuse-015 Meets Primary OS End Point With Sac-TMT in Third-Line or Later Gastroesophageal Adenocarcinoma
3
Dr Iyengar on Oral SERD Implementation in Early-Stage HR+ Breast Cancer
4
Dr Gutierrez on Considerations for Investigating SAR445877 in MSS CRC
5


